Association of specific cytogenetic aberrations with mdr1 gene expression in adult myeloid leukemia and its implication for treatment outcome

Haematologica

Volumn 87, Issue 5, 2002, Pages 455-464

  Schaich, Markus ^a   Harbich Brutscher, Edith ^a   Pascheberg, Ulrich ^a   Mohr, Brigitte ^a   Soucek, Silke ^a   Ehninger, Gerhard ^a   Illmer, Thomas ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Adult; AML; Cytogenetics; mdr1 expression; Treatment outcome

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHROMOSOME ABERRATION; COHORT ANALYSIS; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENE PROBE; HUMAN; HUMAN CELL; KARYOTYPE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYELOID LEUKEMIA; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; CHROMOSOME ANALYSIS; GENE; GENETICS; MIDDLE AGED; MORTALITY; PHYSIOLOGY; SURVIVAL;

ADOLESCENT; ADULT; AGED; CHROMOSOME ABERRATIONS; COHORT STUDIES; CYTOGENETIC ANALYSIS; GENE EXPRESSION; GENES, MDR; HUMANS; LEUKEMIA, MYELOID; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0036093743     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Long-term survival in acute myeloid leukemia: The Eastern Cooperative Oncology Group experience
2. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype
3. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial
4. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study
5. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis
6. Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia
7. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: A Southwest Oncology Group Study
8. Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML)
9. Effects of multidrug resistance gene expression in acute erythroleukemia
10. Localization of multidrug resistance-associated DNA sequences to human chromosome 7
11. Cytogenetic alterations associated with P-glycoprotein- and non-P-glycoprotein-mediated multidrug resistance in SW-1573 human lung tumor cell lines
12. Physical mapping of a tandem duplication on the long arm of chromosome 7 associated with a multidrug resistant phenotype
13. Acquisition of doxorubicin resistance in human leukemia HL-60 cells is reproducibly associated with 7q21 chromosomal anomalies
14. MDR1 expression in poor-risk acute myeloid leukemia with partial or complete monosomy 7
15. Multidrug resistance-1 (MDR1) expression and functional dye/drug efflux is highly correlated with the t(8;21) chromosomal translocation in pediatric acute myeloid leukemia
16. Mutations in ras proto-oncogenes are associated with lower mdt1 gene expression in adult acute myeloid leukaemia
17. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias
18. Expression of PKC isozyme and MDR-associated genes in primary and relapsed state AML
19. A novel method for direct and fluorescence independent determination of drug efflux out of leukemic blast cells
20. Antibodies TC-12 ("unique") and TH-111 (CD96) characterize T-cell acute lymphoblastic leukemia and a subgroup of acute myeloid leukemia
21. Comparison of spectral karyotyping and conventional cytogenetics in 39 patients with acute myeloid leukemia and myelodysplastic syndrome
22. Immunocytochemical detection of the multidrug resistance-associated protein and P-glycoprotein in acute myeloid leukemia: Impact of antibodies, sample source and disease status
23. Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics
24. A new PCR MIMIC strategy to quantify low mdrl mRNA levels in drug resistant cell lines and AML blast samples
25. Multidrug resistance in acute leukemia: A comparison of different diagnostic methods
26. Multicentric evaluation of the MDR phenotype in leukemia
27. Cytogenetic and molecular characterization of random chromosomal rearrangements activating the drug resistance gene, MDR1/P-glycoprotein, in drug-selected cell lines and patients with drug refractory ALL
28. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study
29. The MYND motif is required for repression of basal transcription from the multidrug resistance 1 promoter by the t(8;21) fusion protein
30. Multidrug resistance gene expression in acute myeloid leukemia: Major prognosis significance for in vivo drug resistance to induction treatment
31. P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia